Overview

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

Status:
Completed

Trial end date:
2019-05-31

Target enrollment:

Participant gender:

Summary

This is a prospective, pilot, single center, open-label study in patients with metastatic neuroendocrine tumor. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive a one-time administration of 90Y-DOTA-TOC via the hepatic artery. Participants in the correlative sub-study will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose, and undergo additional imaging and assessment.

Phase:

Early Phase 1

Details

Lead Sponsor:

Thomas Hope

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Edotreotide
Octreotide